Mukul Agrawal picks 1.28% stake in this underperforming stock, drives 14% surge

Shares of Tatva Chintan Pharma Chem, a long-time underperformer currently down 65% from its peak, jumped 13.6% in intraday trade today to Rs 1,062.70 on the BSE after prominent investor Mukul Agrawal acquired a 1.28% stake in the company.

As of the updated shareholding pattern for the quarter ended June 2025, the star investor has bought 3 lakh shares of the company, representing a 1.28% equity stake.

Agrawal's name did not feature in the shareholding pattern available for the January-March quarter, which means either this is an entirely fresh infusion of capital, or he held a <1% stake in the company, which does not require any disclosure.


At the end of the said quarter, the promoters and the promoter group of the company hold a 72% stake in the company, while the remaining 28% rests in the hands of the public shareholders.

India’s domestic mutual funds have slightly reduced their stake in the company, lowering it to 5.07% in June from 5.34% in March. ICICI Prudential has decreased its holding, which now stands at 1.79%, down from 2.03% previously.

Goldman Sachs, through the Goldman Sachs India Equity Portfolio, maintained a 2.59% stake in Tatva Chintan as of the end of the June quarter.

Tatva Chintan Pharma Chem was incorporated in 1996, and it is a manufacturer of a diverse portfolio of structure-directing agents, phase transfer catalysts, electrolyte salts for batteries, and pharmaceutical and agrochemical intermediates and other specialty chemicals.

The shares of Tatva Chintan Pharma Chem have fallen by 6.88% in the last year, but have surged by 21.4% in the current calendar year so far. On a 6-month basis, the stock has rallied by 21%.

Also read: Motherson Sumi, Samvardhana Motherson International shares rise up to 4% on bonus share issue record date

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)